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Congenital hypogonadotropic hypogonadism (CHH) is a rare genetic disorder characterized by infertility and the absence of puberty.
Defects in GnRH neuron migration or altered GnRH secretion and/or action lead to a severe gonadotropin-releasing hormone
(GnRH) deficiency. Given the close developmental association of GnRH neurons with the olfactory primary axons, CHH is often asso-
ciated with anosmia or hyposmia, in which case it is defined as Kallmann syndrome (KS). The genetics of CHH are heterogeneous, and
>40 genes are involved either alone or in combination. Several CHH-related genes controllingGnRH ontogeny encode proteins contain-
ing fibronectin-3 (FN3) domains, which are important for brain and neural development. Therefore, we hypothesized that defects in
other FN3-superfamily genes would underlie CHH. Next-generation sequencing was performed for 240 CHH unrelated probands and
filtered for rare, protein-truncating variants (PTVs) in FN3-superfamily genes. Compared to gnomAD controls the CHH cohort was sta-
tistically enriched for PTVs in neuron-derived neurotrophic factor (NDNF) (p ¼ 1.40 3 106). Three heterozygous PTVs (p.Lys62*,
p.Tyr128Thrfs*55, and p.Trp469*, all absent from the gnomAD database) and an additional heterozygous missense mutation
(p.Thr201Ser) were found in four KS probands. Notably, NDNF is expressed along the GnRH neuronmigratory route in both mouse em-
bryos and human fetuses and enhances GnRH neuron migration. Further, knock down of the zebrafish ortholog of NDNF resulted in
altered GnRH migration. Finally, mice lacking Ndnf showed delayed GnRH neuron migration and altered olfactory axonal projections
to the olfactory bulb; both results are consistent with a role of NDNF in GnRH neuron development. Altogether, our results highlight
NDNF as a gene involved in the GnRH neuron migration implicated in KS.Introduction
Congenital hypogonadotropic hypogonadism (CHH [MIM:
146110, MIM: 147950, MIM: 228300, MIM: 229070, MIM:
244200, MIM: 308700, MIM: 610628, MIM: 612370, MIM:
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614880, MIM: 614897, MIM: 615266, MIM: 615267, MIM:
615269, MIM: 615270, MIM: 615271, andMIM: 616030]) is
characterized by infertility and the absence of puberty. It is a
rare genetic disorder caused by absent secretion or action of
gonadotropin-releasing hormone (GnRH) and is often asso-
ciated with non-reproductive phenotypes. The most
commonly associated phenotype is anosmia, which when
combined with CHH is defined as Kallmann syndrome
(KS [MIM: 308700, MIM: 614897, andMIM: 613301). How-
ever, synkinesia, unilateral renal agenesis, sensorineural
deafness, cleft palate, and other phenotypes are also
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 2019The genetics of CHH are complex, and mutations are
described in more than 401,2 genes. Variable expressivity
both within and between families, as well as incomplete
penetrance, is often present.1,2 Although first described
as a Mendelian disorder, both monogenic and oligogenic
inheritance (i.e., mutations in more than one gene) occur
in CHH.1–3 However, in approximately 50% of affected in-
dividuals, no mutations could be identified in the known
CHH genes.3
To date, the genes implicated in CHH impact GnRH
neuron fate, GnRH neuron migration and/or axon projec-
tion, GnRH neuron homeostasis, and/or gonadotrope
defects. Notably, a unique feature of GnRH neurons
is that they originate in the olfactory placode during
embryonic development and migrate along the terminal
nerve to reach their final destination in the hypothala-
mus.4–6 This complex migratory process is orchestrated
by an intricate network of genes controlling cell signaling,
adhesion, motility, and neurite and axonal elongation.Hospital, 1011 Lausanne, Switzerland; 2Stem Cells andMetabolism Research
; 3Department of Physiology, Faculty of Medicine, University of Helsinki,
elopment and Plasticity of the Neuroendocrine Brain, Unité 1172 Lille,
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ANOS1 (formerly known as KAL1 [MIM: 300836])
was the first gene implicated in KS.7,8 ANOS1 encodes
anosmin-1, which belongs to the fibronectin-3 (FN3)
superfamily. Members of this family also include extra-
cellular-matrix molecules and cell-surface hormone and
cytokine receptors,9 and the evolutionarily conserved
FN3 domain is typically involved in protein-protein in-
teractions related to cell adhesion, migration, and em-
bryonic development.10 Notably, mutations in several
additional genes within this family have been associated
with CHH; such genes include AXL [MIM: 109135],
FLRT3 [MIM: 604808], LEPR [MIM: 601007], and most
recently, DCC [MIM: 120470].2 Thus, we hypothesized
that other proteins containing FN3 domains would also
be involved in GnRH neuron ontogeny and contribute
to the pathogenesis of CHH. Through a gene-based
burden analysis of FN3-superfamily genes, we identified
NDNF—a neurotrophic factor involved in neuron sur-
vival, migration, and neurite outgrowth11—as a locus
for CHH.Subjects and Methods
Subjects
A total of 240 unrelated CHH probands (140 KS and 100 normos-
mic CHH [nCHH], 179males and 61 females) were included in the
study. 222 individuals were from the Centre Hospitalier Universi-
taire Vaudois, and 85% were of European descent. The remaining
18 were from the Helsinki University Hospital and were of Finnish
origin (See Supplemental Material and Methods). Diagnoses of
nCHH and KS were made as previously described,1,12,13 and family
members were recruited when possible. All subjects provided
written informed consent, and the study was approved by the
institutional ethics committee at the University of Lausanne and
the Helsinki University Central Hospital.
DNA Sequencing and Bioinformatic Analyses
Genomic DNA was extracted from peripheral blood (or saliva)
through the use of commercially available QIAGEN kits according
to the manufacturer’s protocol. Whole-exome sequencing (WES),
alignment, and variant calling were performed as previously
described.14,15 All variants were then annotated with minor-allele
frequencies (MAFs) from gnomAD (see Supplemental Material and
Methods for details). Protein-truncating variants (PTVs; defined as
stop gain, frameshift, and acceptor-donor splice sites 5 2 bp from
the exon) with MAF% 0.1% were identified in the 204 FN3-super-
family genes obtained from the Interpro database (IPR003961, see
Table S1). A gene-based burden analysis for the FN3-superfamily
genes was performed with a two-tailed Fisher’s exact test in CHH
probands versus controls (gnomAD). To correct for multiple
testing, we set a significance threshold at p < 2.45 3 104. Candi-
date FN3 genes were then prioritized according to the following
criteria: (1) a significant enrichment of mutations in the CHH
cohort as assessed with the gene-based burden test16 and (2) muta-
tions in FN3 candidate genes that are present in individuals for
whom the CHH genes do not contain any mutations that would
fully explain their phenotype (see Supplemental Material and
Methods). All variants in NDNF were confirmed with bi-direc-
tional Sanger sequencing.The AmCell-Based Functional Assays
NDNF Protein Expression and Cell-Surface Expression
A double FLAG tag was added to the N terminus of human NDNF
(GenBank: NM_024574.3) in the pCDNA3.1 expression plasmid.
We used site-directed mutagenesis to introduce the mutations
into the construct by using a QuickChange II Site-Directed
Mutagenesis Kit (Stratagene) according to the manufacturer’s pro-
tocol. To assess the impact of the mutants on the expression and
secretion of NDNF, we performed western-blot and cell-surface
expression assays as previously described.14,17
Reporter Gene Assay
We used a nuclear factor of activated T cells (NFAT)-luciferase-
based reporter bioassay to assess the activity of the wild-type
(WT) and mutant NDNF in COS7 cells treated with increasing
doses of FGF8 (addgene plasmid 10959).18,19 NFAT is a reporter
for the PLCg/Caþ2 cascade downstream of FGF8/FGFR1 signaling
(see Supplemental Material and Methods).
Recombinant NDNF Protein Production
Full-length untagged 568 amino acid recombinant human NDNF
protein (Uniprot: Q8TB73) was produced with the QMCF stable
episomal expression system after cDNA codon optimization was
performed in CHO cells by Icosagen (see Supplemental Material
and Methods).
Cell-Culture and Migration Assays
Transwell experiments were performed with the GN11 cell line as
previously reported.20 In brief, GN11 cells were seeded on the up-
per side of 8-mm-pore filters in transwell chambers and incubated
for 8 h in 10% fetal bovine serum (FBS) DMEMwith or without re-
combinant NDNF (10, 100, 200, 500 ng/mL; Icosagen). rNDNF
was added either to both chambers (n ¼ 5 for each dose) or only
in the upper chamber (n ¼ 5 for each dose). GN11 cells that
migrated to the lower side of the filter were then fixed in cold
100% methanol for 5 min, and the nuclei were stained with
DAPI for subsequent quantitative analysis. Data were compared
by one-way ANOVA for multiple comparisons.
We performed three-dimensionalmatrixmigration assays by co-
culturing aggregates of GN11 cells with aggregates of COS7 cells21
transfected with plasmids encoding either mutated NDNF or WT
NDNF as a control. We created cell aggregates by resuspending
GN11 and COS7 cells in 2 mL or 5 mL of growth-factor-free Matrigel
(BD Biosciences; 106 cells/mL), respectively, placing them on a cul-
ture dish, and inverting them until the gel had set. The droplets
were then covered with a growth-factor-reduced Matrigel coating
and kept in culture for 72 h. For analysis, the aggregates were fixed
with paraformaldehyde (PFA) 4% for 40 min and stained with
Alexa Fluor 594 Phalloidin (Invitrogen) for 30 min at room
temperature. Photographs were taken for quantitative analysis
with ImageJ. For illustration, photomicrographs have been digi-
tally inverted, and a pseudo-color (purple) has been superimposed
so that the cell distribution is highlighted.
Zebrafish Experiments
Animal Model
We used the OMP2k:gap-CFPrw034 and TRPC24.5k:gap-Venusrw037
transgenic zebrafish strains22–24 as reporters to visualize, respec-
tively, the OMPþ and the Trpc2þ neurons and their axonal
projections of the zebrafish olfactory system during embryonic
development, as previously described.25 We used the GnRH3::GFP
strain to visualize the zebrafish GnRH3þ neurons.25,26 A conven-
tional antisense morpholino oligo (MO)-mediated strategy was
used for down-modulation of z-ndnf.27,28 This involved two previ-
ously validated anti-z-ndnfMOs—one targeting the splice junctionerican Journal of Human Genetics 106, 58–70, January 2, 2020 59
between intron 3 and exon 4 and leading to a premature stop
codon upstream of the homeodomain and a second that anneals
to the ATG start codon and prevents translation.29 As a control,
a sequence previously shown to have no effect was used.30 Zebra-
fish embryos were injected at the one-cell stage with 4 ng of
control or anti-z-ndnf MO, and then the number, morphology,
and position relative to the olfactory placode of GFPþ cells in
the frontonasal piece were examined at 72 hours post-fertilization
(hpf), as previously described.25,30
Real-Time qPCR Analysis for Coding mRNAs
Relative mRNA levels of z-OMPa, z-OMPb, z-Trpc2, and z-HoxA10b
were determined by real-time qPCR in total RNA samples extracted
from the heads of z-ndnf- or control-MO injected zebrafish em-
bryos, as previously described.25 The abundance of z-b actin
mRNAs was used for normalization because doing so was previ-
ously shown to be the best method.31 The Roche UPS online
tool was used for primer design (Supplemental Material and
Methods), and the DDCt formula (ABI software version 2.1,
Applied Biosystems) was used for data analysis.25
Expression Studies in Mice
Mouse Model
GnRH-GFP32 mice were graciously provided by Dr. Daniel J. Spergel
(Section of Endocrinology, Department of Medicine, University of
Chicago). Mice were housed under specific pathogen-free condi-
tions in a temperature-controlled room (21C –22C) with a
12 h light/dark cycle and ad libitum access to food and water. An-
imal studies were approved by the Institutional Ethics Committees
of Care and Use of Experimental Animals of the University of Lille
2. All experiments were performed in accordance with the guide-
lines for animal use specified by the European Union Council
Directive of September 22, 2010 (2010/63/EU).
Fluorescence-Activated Cell Sorting and Gene-Expression Analysis
GnRH-GFP neurons were isolated from embryos at embryonic
days 14.5 and 18.5 (E14.5 and E18.5) through the use of a
previously validated fluorescence-activated cell sorting (FACS) pro-
tocol.33 Reverse transcription and linear pre-amplification were
performed, and Ndnf expression was measured by qRT PCR with
Taqman expression assays. Data were compared by one-way
ANOVA for multiple comparisons and a subsequent Tukey’s
least-significant-difference post-hoc test. A detailed description is
provided in the Supplemental Material and Methods.
Collection and Processing of Human Fetuses
Tissues were made available in accordance with French bylaws
(Good Practice Concerning the Conservation, Transformation, and
Transportation of Human Tissue to Be Used Therapeutically, published
on December 29, 1998). The studies on human fetal tissue were
approved by the French agency for biomedical research (Agence
de la Biomédecine, Saint-Denis la Plaine, France, protocol
n: PFS16–002). Non-pathological human fetuses (7 and 11 gesta-
tional weeks (GW), n ¼ 3) were obtained from voluntarily termi-
nated pregnancies after written informed consent was obtained
from the parents (Gynaecology Department, Jeanne de Flandre
Hospital, Lille, France). Fetuses were fixed by immersion in 4%
PFA at 4C for 5 days. The tissues were then cryoprotected in
PBS containing 30% sucrose at 4C overnight, embedded in
Tissue-Tek OCT compound (Sakura Finetek), frozen in dry ice,
and stored at80C until sectioning. Frozen samples were cut seri-
ally at 20 mm with a Leica CM 3050S cryostat (Leica Biosystems
Nussloch GmbH) and immunolabeled, as described above and as
previously described,34,35 with the following primary antibodies:60 The American Journal of Human Genetics 106, 58–70, January 2, 2guinea pig anti-GnRH (dilution 1:10000), a kind gift from Erik
Hrabovszky (Institute of Experimental Medicine, University of
Budapest); monoclonal mouse TUJ1 (Sigma, 1:1000); and rabbit
polyclonal NDNF (1:200; Cat: ARP68872_P050, Aviva Systems
Biology).
Ndnf Knockout Mice
A Ndnf knockout (KO) mouse strain on the C57BL/6N genetic
background was obtained from a NorCOMM B6N-derived C2 ES
cell line generated by Geoffrey Hicks at the University of Manitoba
(NorCOMM design ID N02206). Most of the coding part of Ndnf
was deleted by homologous recombination. The targeting cassette
replaced part of intron 3, the coding sequence of exon 4, and part
of the 30 UTR of the gene with an E. coli lacZ reporter construct,
thus resulting in a non-functional gene product. Microinjections
and production of KO mice were carried out at the Biocenter
Oulu Transgenic Core Facility. Genotyping of the mice was per-
formed as described in the Supplemental Material and Methods.
The mice were housed with a 12 h light/dark cycle and ad libitum
access to food and water. Both heterozygous and homozygous
Ndnf KO mice appeared grossly normal and were able to produce
viable pups.
All experiments were performed according to the guidelines for
animal experiments at the University of Helsinki and under a li-
cense from the Finnish Review Board for Animal Experiments.iDISCO Whole-Mount Staining
Experiments were performed as previously described36 and are
detailed in Supplemental Material and Methods.GnRH Cell Counting
Embryos were harvested at embryonic day 13.5 from Ndnf trans-
genic mice (wild-type, n ¼ 5; heterozygous, n ¼ 7; and homozy-
gous, n¼ 4). Heads from the embryos were washed thoroughly in
cold 0.01 M PBS, preserved in fixative solution (4% PFA, 0.01 M
PBS [pH 7.4]] for 6–8 h at 4C, and immunolabelled for GnRH
and peripherin through the use of iDISCO as described above. Pri-
mary antibodies used for these experiments were guinea pig anti-
GnRH (dilution 1:10000), which was a kind gift from Erik Hra-
bovszky (Institute of Experimental Medicine, University of Buda-
pest) and rabbit polyclonal anti-peripherin (Millipore, 1:1000).
Quantitative analysis of GnRH neuronal number and location
was performed over four regions: nose, olfactory bulb, ventral
forebrain, and cortex. Both coronal and sagittal views were used
for confirming accurate GnRH neuron localization, and counting
was performed every 20 planes on the 43 zoom tiff series with Fiji
and the Cell Counter plug-in.Statistical Analysis
Sample sizes for neuroanatomical studies, gene expression, and
in vitromotility analyses were estimated on the basis of prior expe-
rience and similar published studies. For the mouse work, typi-
cally, embryos taken from at least two different litters for each
group were used.
Quantitative RT-PCR gene-expression data were analyzed with
SDS 2.4.1 and Data Assist 3.0.1 software (Applied Biosystems).
All other analyses were performed with Prism 5 (GraphPad soft-
ware). Datasets were assessed for normality (Shapiro-Wilk test)
and variance. When appropriate, a one-way ANOVA followed by
Bonferroni or Dunnets’s post-hoc correction was performed as
indicated in the figure legends. Exact p values and adjusted020
Figure 1. Exome Sequencing Identifies
NDNF Mutations in KS Patients
(A) Filtering strategy for identifying novel
candidate CHH-related genes.
(B) Manhattan plot of gene-based burden
testing for FN3-superfamily genes. The red
and blue dotted lines indicate the threshold
for statistical significanceaftercorrection for
multiple testing (red: n¼ 20,000, p< 2.53
106; blue: n ¼ 204, p < 2.453 104).
(C) Schematic depiction of NDNF mRNA
and protein; identified mutations are indi-
cated. SP, signal peptide; FN3, fibronectin
type 3 domain.
(D) Alignment of partial protein sequences
of NDNF orthologs shows that the
p.Thr201Ser mutation (asterisk) affects
evolutionarily conserved amino acid resi-
dues across vertebrates (colored high-
lighting, turn propensity).
(E) Pedigrees of four families harboring
NDNF mutations. Phenotypes are indi-
cated by hatched symbols as shown
in the legend (bottom), and arrows indi-
cate the probands. HH, hypogonadotropic
hypogonadism; CDGP, congenital delay of
growth and puberty.p values are given in the figure legends where possible. awas set at
0.05 for all experiments except where otherwise specified.Results
Gene-Based Burden Testing Identifies Neuron-Derived
Neurotrophic Factor as a Putative CHH-Associated Gene
Given that several CHH-associated genes encode proteins
containing FN3 domains, WES data from 240 unselected
CHH-affected individuals (143 KS and 97 normosmic
CHH) were filtered for rare (MAF < 0.1% in gnomAD)
PTVs in the 204 FN3-superfamily genes from the Interpro
database (Table S1). Next, a gene-based burden analysis
comparing the frequency of PTVs in affected individuals
to that of individuals in the gnomAD control database
was performed. A statistical enrichment for PTVs in
CHH-affected probands was demonstrated for three FN3
genes (Figures 1A and 1B), including two known CHH-
associated genes (ANOS1, p ¼ 2.88 3 106; AXL, p ¼
7.46 3 105) and one novel gene, NDNF [MIM: 616506]
(p ¼ 1.40 3 106). Notably, none of the probands carryingThe American Journal of HumanNDNF PTVs had mutations in the
known CHH-affected genes.
Individuals with KS Harbor NDNF
Mutations
In addition to the three heterozygous
PTVs identified in CHH probands in
the burden analysis (GenBank:
NM_024574.3; c.184A>T [p.Lys62*],
c.381del [p.Tyr128Thrfs*55],
c.1406G>A [p.Trp469*]), we identi-fied one additional heterozygous missense mutation
(c.602C>G [p.Thr201Ser]) predicted to be deleterious in
4/6 programs (PolyPhen-2, MutationTaster, LRT, and
CADD).
The genetic and clinical information of the probands
harboring NDNF mutations is summarized in Table 1 and
Figure 1E. Notably, all four probands exhibit severe
GnRH deficiency and anosmia (related to KS). In addition
to prepubertal testes, the male probands had cryptorchi-
dism and micropenis, suggesting an abnormal GnRH acti-
vation during mini-puberty.2 The female proband
presented with primary amenorrhea at age 17 (see the
Supplemental Information for a description of affected in-
dividuals). Furthermore, three of these probands’ family
members (F1:I,1; F3:II,1; and F3:II,2) also carry NDNF mu-
tations and have partial phenotypes (i.e., anosmia or
constitutional delay of puberty), suggesting an auto-
somal-dominant inheritance with variable expressivity
(Figure 1E). The presence of asymptomatic carriers
(F2:I,1; F3:I,1; and F3:III,3) is consistent with incomplete
penetrance.Genetics 106, 58–70, January 2, 2020 61
Table 1. Phenotype and Genotype of Four Probands with Heterozygous NDNF Mutations
Subject Sex NDNF Mutation MAF Diagnosis Inheritance Other Phenotypes
F1:II,1 M p.Lys62* absent KS familial micropenis crytorchidism
F2: II,1 M p.Tyr128Thrfs*55 absent KS sporadic cryptorchidism
F2:II,3 F p.Trp469* absent KS familial
F3:III,1 M p.Thr201Ser 0.10% KS familial micropenis crytorchidism
Abbreviations are as follows: MAF, minor-allele frequency in gnomAD; KS, congenital hypogonadotropic hypogonadism plus anosmia (Kallmann syndrome); N/A:
no DNA available; M, male; F, female.Overall, NDNFmutations are present in nearly 2% of the
CHH cohort (4/240). When only KS probands are consid-
ered, the frequency increases to ~3% (4/140).Truncating NDNF Mutations Result in Loss of Function
In Vitro
To evaluate the functionality of NDNF mutants in vitro, we
assessed COS7 cells that had been transiently transfected
with WT and mutant tagged NDNF cDNA for ectopic
NDNF protein synthesis and secretion. Western-blot
analysis of WT-transfected COS7 cells showed that NDNF
protein is detected in both the conditioned medium and
in the cell extract (Figures 2A and 2B). A radiolabeled-anti-
body binding assay showed expression at the cell surface
(Figure 2C), suggesting that NDNF has either a direct or
an extracellular-matrix-mediated interaction with cell-sur-
face proteins.
Among the PTVs, the Lys62* and Tyr128Thrfs*55 mu-
tants were not detected in whole cell extract or condi-
tioned medium, suggesting disrupted protein synthesis or
rapid degradation. In contrast, the Trp469* mutant is ex-
pressed in both the cell extract and conditioned medium
but exhibits a reduced expression at the cell surfaceerase reporter, FGFR1, and increasing doses of WT NDNF and treated
(E) Trp469* fails to inhibit FGF8 signaling. COS7 cells were transfecte
not significant.
62 The American Journal of Human Genetics 106, 58–70, January 2, 2(50%). The Thr201Ser mutant displays no overall expres-
sion alterations (Figures 2A–2C).
We further examined the effect of WT NDNF on
PLCgamma/Ca2þ pathway activation after FGF8 stimula-
tion. As previously shown, FGF8 stimulation of FGFR1-
transfected COS7 cells elicits a dose-dependent activation
of the NFAT-luciferase reporter (Figure 2D).37 Notably,
when WT NDNF is co-transfected, the FGF8-induced
NFAT reporter activity is inhibited in a dose-dependent
fashion (Figure 2D). This assay was then used for evalu-
ating the functionality of the expressed NDNF mutants.
Whereas WT NDNF suppressed FGF8 signaling by 30%,
the Trp469* mutant had no effect on FGF8 signaling,
consistent with loss of function (Figure 2E). The Thr201Ser
mutant and the WT suppressed FGF8 signaling similarly.
Taken together, these combined in vitro results validate
the three truncated mutants as causing a loss of function.z-ndnf Contributes to GnRH Neuron Migration in
Zebrafish
Using a previously validated MO-based strategy,29 we
depleted z-ndnf in zebrafish embryos and observed no
gross morphological defects. We therefore depleted z-ndnfFigure 2. Truncated NDNF Variants
Result in a Loss of Function In Vitro
(A and B) Representative experiments
showing ectopic expression and secre-
tion of NDNF protein. COS7 cells were
transiently transfected with 5 or 100 ng
of WT or mutant NDNF and analyzed
by western blotting. The Lys62* and the
Tyr128Thrfs*55 mutants were not
detected. Thr201Ser and Trp469* were
expressed at levels similar to those of
the WT (means of five independent
experiments).
(C) Cell-surface antibody binding of NDNF
protein (means of four independent exper-
iments). The expression of the truncated
mutant Trp469* was decreased, whereas
Thr201Ser was expressed at levels similar
to those of the WT. ***p < 0.001; ns, not
significant.
(D) NDNF suppresses FGF8 signaling in a
dose-dependent manner. COS7 cells were
transiently co-transfected with NFAT-lucif-
with FGF8. ***p < 0.001; ns, not significant.
d as described with 10 ng of WTor mutant NDNF. ***p < 0.001; ns,
020
Figure 3. Depletion of z-ndnf in Zebra-
fish Resulted in Altered GnRH Neuron Po-
sition
(A) Schematic depiction showing the fron-
tal view position of GnRH3::GFPþ neu-
rons (green) relative to the olfactory
placode (OPL), the olfactory bulb (OB),
and the olfactory nerves (yellow and
blue). The anterior commissure (AC) is
shown at the base of the OB, GL, and
glomeruli.
(B) Schematic depiction illustrating the
ventral view used for fluorescence imaging.
(C) Micrographs of GnRH3:GFP zebrafish
embryos at 72 hpf. The upper panels de-
pict embryos injected with a control MO
showing no significant alteration (white
arrows), and the lower panels show em-
bryos injected with anti-z-ndnf MO. The
red arrows indicate mis-positioned GFPþ
neurons.
(D) Percentage of embryos with ‘‘scattered
GnRH neuron’’ phenotype in control
versus anti-z-ndnf MOs, p < 0.05.
(E) Number of GFPþ neurons per embryo;
there is no significant difference between
the two groups.
(F) Whole-mount bright-field micrographs
of control and injected embryos; The im-
age shows normal embryonic morphology
and size at 72 hpf.in GnRH3::GFP transgenic embryos to specifically examine
the number, position, and morphology of GnRH3-GFPþ
neurons. Injection of anti-z-ndnf MO did not affect
GnRH3-GFPþ cell number (average 16 5 1 per embryo
at 72 hpf) or GFP fluorescence intensity (used here as a re-
porter of GnRH3 promoter). However, it did affect GnRH3-
GFPþ neuron positioning along the known migratory
route of the terminal nerve (Figure 3). Indeed, GnRH3-
GFPþ neurons in embryos treated with control MO form
a discrete aggregate between the olfactory placodes and
the olfactory bulbs. In contrast, the z-ndnf embryos
frequently exhibit severely mis-positioned or scattered
GnRH3-GFPþ neurons (i.e., > 2 mis-positioned neurons
in one half-embryo; 22/40 embryos [54%] in z-NDNF-
MO versus 1/25 embryos in controls [4%]), consistent
with a specific role of NDNF in the migration of GnRH
neurons.NDNF Is Expressed along the Migratory Route of
Embryonic GnRH Cells in Mice and Humans
To determine whether Ndnf is expressed along the GnRH
migratory pathway duringmammalian embryonic develop-
ment, we used a GnRH::GFP mouse model combined with
FACS and qRT-PCR (Figures 4A and 4B). At E14.5, GnRH
neurons are distributed throughout their migratory route,
with approximately half in the nose and half in the brain
(Figure 4A). Ndnf mRNA expression was very low in
GnRH-GFP migratory cells in the nose, whereas Ndnf was
strongly expressed by GFP-negative cells (e.g., olfactory
and vomeronasal neurons, mesenchymal cells, and endo-
thelial cells; Figure 4B). In the basal forebrain, Ndnf levelsThe Amwere low in both GnRH neurons and GFP-negative cells,
suggesting that the major source of Ndnf at this stage is
the nasal compartment. At E18.5, the GnRHmigratory pro-
cess is largely complete, and the majority of GnRH neurons
have reached their target location in the hypothalamus. At
this time point, Ndnf expression was significantly higher in
GFP-negative cells than in GnRH neurons (Figure 4B).
Usingdouble-immunofluorescence,wenextevaluated the
expressionpatternofNDNF in thenasal compartmentofhu-
man fetuses (7 and 11 GW) together with the expression of
GnRH and TUJ1, a marker of the developing olfactory and
vomeronasal systems and differentiated neurons (Figures
4C and 4D). NDNF was found in the developing olfactory
epithelium, in the vomeronasal organ (VNO), and along
the vomeronasal/terminal nerve (Figures 4C and 4D). At 7
GW, GnRH neurons were observed leaving the vomeronasal
organ inclosemorphological association toNDNF-immuno-
reactive axons (Figure 4C). However, NDNF expression was
absent from humanmigratory GnRH neurons.NDNF Repels Migrating GnRH Cells in vitro
Since NDNF is highly expressed by olfactory and vomero-
nasal epithelia when GnRH neurons emerge from the
VNO, we hypothesized that this soluble molecule could
trigger GnRH directional migration by repelling these neu-
rons from their site of origin and differentiation toward the
forebrain (fb). We used GN11 cells, an in vitro model of
migratory GnRH cells,38 in a transwell plate assay to eval-
uate the response to increasing doses of recombinant hu-
man NDNF (10, 100, 200, 500 ng/mL). We added NDNF
to either the upper chamber alone or the upper and lowererican Journal of Human Genetics 106, 58–70, January 2, 2020 63
Figure 4. NDNF Expression Delineates
the Migratory Route of Embryonic GnRH
Cells in Mice and Humans and Repels
Immortalized GnRH Cell Migration
(A) Schematic depiction of the GnRH
migratory pathway in E14.5 mouse em-
bryos (sagittal view).
(B) GFP-positive GnRH neurons and GFP-
negative cells were isolated by FACS from
the nasal region of E14.5 embryos (n ¼ 3
or 4) and from the developing preoptic
area of E14.5 (n ¼ 3 or 4) and E18.5 (n ¼
3 or 4). Real-time PCR analysis helped to
determine the expression levels of Nndf
mRNA in GFP-positive and -negative cells.
Values are expressed relative to values, set
at 1, in GnRH neurons at E14.5 and are
shown as means 5 SEM. One-way
ANOVA followed by Tukey’s Honest Signif-
icant Difference post-hoc analysis was
used for comparing groups. *p < 0.05.
(C) Representative coronal section of a hu-
man fetus (HF) at 7 gestational weeks. The
section is immunolabeled for GnRH and
NDNF (n ¼ 3). nmc, nasal midline carti-
lage; vno, vomeronasal organ.
(D) Representative coronal section of a hu-
man fetus at 11 gestational weeks. The sec-
tion is immunolabeled for TUJ1 andNDNF
(n ¼ 3). tn, terminal nerve; fb, forebrain;
oe, olfactory epithelium.
(E) For migration analysis, GN11 cells were
used in a transwell assay in the presence or
absence of recombinant NDNF (blue, both
chambers).
(F) GN11 migration with NDNF in the up-
per chamber only (n ¼ 5 for each treat-
ment condition); *: p < 0.05, **: p <
0.01, ***: p < 0.001, one-way ANOVA fol-
lowed by Tukey’s post-hoc test. Scale bars
in (C) represent 30 mm; scale bars in
(D) represent 100 mm.compartments of a transwell plate (Figures 4E and 4F) to
specifically evaluate whether NDNF affects GN11 motility.
This action can be through either chemokinesis or direc-
tional chemotaxis.
Exposure to increasing doses of NDNF plated in both
chambers resulted in a significant reduction of GN11 cell
migration to the bottom of the polycarbonate filter in com-
parison to what occurred in control conditions. This could
be due to either an inhibition of cell motility or a repellent
NDNF activity that neutralizes oriented migration when
NDNF is present in both chambers. To investigate this
further, we performed transwell migration assays by
plating the same doses of NDNF in only the upper chamber
in serum-free conditions (SFM). NDNF produced a signifi-
cant increase in migration as compared to that in control
conditions (Figure 4F). In combination with the expression
data, these results suggest that NDNF acts as a chemorepel-
lent molecule on GnRH cell migration.
To assess the functional consequences of NDNF
mutants on GN11 directional migration, we performed
three-dimensional matrix assays by co-culturing aggre-64 The American Journal of Human Genetics 106, 58–70, January 2, 2gates of GN11 cells for 72 h with aggregates of COS7 cells
transiently transfected with a mock construct or with WT
or mutant NDNF (Figure 5). Compared to the mock treat-
ment, the WT NDNF GN11 cells displayed an asymmet-
rical distribution, with fewer cells on the proximal side
andmore cells on the distal side (Figure 5B). This asymmet-
rical migration confirmed the chemo-repulsive action of
NDNF on immortalized GnRH neurons. However, this
directional effect was prevented when GN11 cells were
co-cultured with COS7 cells expressing any of the NDNF
mutants. These results show that WT NDNF acts as a che-
morepellent for GnRH cell migration and that this effect
is lost in NDNF mutants, including the Thr201Ser mutant.
Loss of Ndnf in Murine Embryos Alters GnRH Neuron
Migration and the Olfactory Axonal Scaffold
We then sought to determine whether genetic deletion of
Ndnf in a murine model would lead to defects in GnRH
neuronal migration. We performed a detailed analysis
of E13.5 Ndnf WT, heterozygous, and homozygous
mutants by using whole-mount immunostaining for020
Figure 5. NDNF Mutants Fail to Induce
GnRH Cell Migration In Vitro
(A) Schematic illustration of the three-
dimensional co-cultures of COS7 and
GN11 cell aggregates. After 72 h in culture,
the GN11 migration area is measured in
the proximal (red) and distal (blue) quad-
rants as the surface covered by GN11 cells
minus the aggregate inner mass area.
(B) Representative pictures of three-dimen-
sional matrix co-cultures of GN11 cells
with COS7 cells stained withDAPI and
phalloidin red. For illustration, photo-
graphs have been digitally inverted, and
a pseudo-color (purple) has been superim-
posed so that cell distribution is high-
lighted.
(C) Quantitative analysis of GN11 cell-
migration aggregates (n ¼ 12 per group)
normalized and compared to the control
condition (MOCK). Values are expressed
as means 5 SEM and analyzed by two-
way ANOVA followed by Sidak’s multiple-
comparisons test. **p < 0.01; ****p <
0.0001. d, distal side; p, proximal side.GnRH and peripherin, a neuron-specific intermediate fila-
ment protein expressed by rodent sensory and autonomic
axons,39 including the developing olfactory nerve (ON)
and the vomeronasal nerve (VNN).35,40 This was followed
by iDISCO tissue clearing36 and light-sheet microscopy
(LSM) (Figures 6A–6D; Videos S1 and S2). In Ndnfþ/þ em-
bryos, GnRH neurons were more clustered in the
nasal compartment, and fewer GnRH cells reached the
developing hypothalamus at this embryonic stage (Figures
6A–6D, arrowheads; Videos S1 and S2). Moreover, in
Ndnfþ/þ embryos, peripherin-positive fibers were seen to
almost completely innervate the olfactory bulb (Figures 6E
and 6G, arrows), whereas in Ndnf/ mice olfactory axons
only partially innervate their target tissues (Figures 6F and
6H, arrows). The intracranial projections of the terminal
and vomeronasal nerve (tn/vnn) did not show any abnor-
malities in Ndnf/embryos as compared to Ndnfþ/þ em-
bryos (Figures 6E and 6F).
We then counted the number of GnRH neurons in these
embryos and found a comparable total number of GnRH
neurons between all genotypes (Figure 6I), indicating
that a lack of Ndnf has no effect on GnRH neuron survival.
However, inNdnf/ mice the number of GnRH cells in the
nasal and olfactory bulb region was significantly greater
than in Ndnfþ/þor Ndnfþ/mice (Figure 6J), respectively.
As a result, fewer GnRHneurons reached the hypothalamic
region in theNdnf-null embryos (Figure 6J). The accumula-
tion of GnRH neurons in the more rostral regions and
decreased cell number within the ventral forebrain is sug-
gestive of a delayed GnRH cell migration in Ndnf / mice.
Altogether, these experiments revealed that genetic
invalidation of Ndnf leads to abnormal development of
the olfactory system and defective GnRH migration to
the hypothalamus.The AmDiscussion
NDNF, the neuron-derived neurotrophic factor, was identi-
fied as a CHH gene via a strategy includingWES and bioin-
formatics and focusing on genes in the FN3 superfamily.
We first identified an enrichment of NDNF PTVs in our
CHH cohort versus gnomAD. The three unrelated CHH
probands (~2%) harboring heterozygous protein-trun-
cating NDNF mutations had severe GnRH deficiency and
anosmia consistent with Kallmann syndrome. Because
Ndnf had been previously implicated in neuron structural
plasticity, we then silenced z-ndnf in zebrafish, which re-
sulted in a defect in GnRH neuron migration. In vitro
studies established NDNF as a chemorepellent factor; com-
bined with this protein’s high expression in the nasal
compartment, this finding could indicate a role for
NDNF in initiating GnRH neuron migration.
CHH is a complex genetic disorder for which >40 associ-
ated loci, each accounting for less than 10% of cases, have
been identified to date. Importantly, about half of persons
with CHH do not carry mutations in the known CHH-asso-
ciated genes.3 Historically, cytogenetics,41–45 linkage
studies,46,47 homozygosity mapping,48 candidate gene ap-
proaches,1,49 and other strategies have been used for the dis-
covery of new genes related to CHH. Recently, Guo et al.
applied collapsed gene-based burden testing to a population
of 393 unrelated CHH probands and demonstrated signifi-
cant associations to only three of the known CHH-related
genes—FGFR1 [MIM: 136350], TACR3 [MIM: 162332], and
GNRHR [MIM: 138850].16 Limitations of the study included
a small population size and an inability to detect significant
associations to most of the known CHH-related genes. Our
current strategy combined collapsed gene-based burdenerican Journal of Human Genetics 106, 58–70, January 2, 2020 65
Figure 6. GnRH Migration and Olfactory Innervation Are Perturbed in Ndnf/ Mice
(A–D) Representative whole-body iDISCO experiments in E13.5 Ndnfþ/þand Ndnf /embryos immunolabelled for peripherin (white)
andGnRH (green). (A andC) Horizontal projections of the embryo heads. (B andD) Lateral projections of the embryo heads. Arrowheads
in A–D indicate GnRH cells located in the nasal and brain regions.
(E and F) High-magnification photomicrographs (lateral view) depicting olfactory and vomeronasal axon innervations (peripherin-
positive) to the olfactory bulb and to the presumptive hypothalamus (terminal and vomeronasal nerve, tn/vnn) in E13.5 Ndnf þ/þ(E)
and Ndnf /embryos (F).
(G and H) High-power view (frontal view) showing olfactory axon innervations of the OB in E13.5 Ndnf þ/þ(G) and Ndnf / (H) em-
bryos. Arrows in (E)–(H) indicate noticeable differences in peripherin-positive fibers innervating the OB.
(I) Quantification of the total number of GnRH-immunoreactive neurons inNdnf þ/þ(n¼ 6),Ndnf þ/(n¼ 7), andNdnf/ E13.5 embryos
(n ¼ 4). Data are represented as means 5 SEM. Statistical analysis was performed by one-way ANOVA (F2,14 ¼ 0.9, p ¼ 0.4) followed by
Fisher’s LSD post-hoc test.
(J) Quantitative analysis of GnRH neuronal distribution throughout the migratory pathway in the three experimental populations. Sta-
tistical analysis was performed by two-way ANOVA (F4,42 ¼ 7.58, p ¼ 0.0001) followed by Fisher’s LSD post-hoc test (*p < 0.05, **p <
0.005, ***p < 0.001). Scale bars (A–D) represent 200 mm.testing with a targeted gene population (FN3 superfamily).
This approach was based on the observation that several
proteins that were involved in GnRH neuron migration
and that were previously implicated in CHH (e.g., such pro-
teins include ANOS1, AXL, DCC, and FLRT3) contain FN3
domains. Through the study of 240 CHH-unrelated pro-
bands, we demonstrated a statistical enrichment for PTVs
in NDNF, which encodes a secreted glycosylated disulfide-
bond protein containing FN3 domains. In addition, two
known FN3-containing CHH-related genes (ANOS1 and
AXL) also gave positive associations.16
The enrichment of PTVs inNDNF suggests that deletions
in NDNF might explain some cases of CHH and will be66 The American Journal of Human Genetics 106, 58–70, January 2, 2further studied via whole-genome sequencing. Indeed,
pathogenic deletions have been reported for other genes
underlying CHH (e.g., such genes include ANOS1,50
SEMA3A,51 PROKR2,52 FGFR1,53 and, SOX1054).
The four probands carrying a heterozygous NDNF muta-
tion exhibited both CHH and anosmia (i.e., KS), a condi-
tion related to defects in the embryonic development of
GnRH neurons.1 Overall, ~3% of individuals with KS har-
borNDNFmutations. Notably, several family members car-
rying NDNF mutations also exhibit a partial phenotype
(i.e., delay of puberty and/or anosmia), consistent with
an autosomal-dominant mode of inheritance with variable
expressivity and incomplete penetrance—features seen in020
other CHH-related genes.1,2 None of the probands harbor
mutations in other known CHH-related genes.1,2,55 As
new research disentangles the NDNF signaling pathway
(including its receptor), novel genetic interactions might
be uncovered. Further investigations are needed to dissect
the contribution of genetic (e.g., oligogenicity, structural
variants, and eQTLs) and environmental factors (e.g.,
stress, nutrition, and endocrine disruptors) potentially
modifying the phenotype of persons carrying NDNF loss-
of-function mutations.
NDNF is a secreted neurotrophic factor that can pro-
mote neuron migration, growth, and survival, as well
as neurite outgrowth.11 Ndnf is highly expressed in
the olfactory bulb, Cajal-Retzius cells, hippocampus,
and cerebellum during murine embryogenesis.11 Here-
in, we show that NDNF is expressed in the nasal region
after formation of the olfactory placode in mice and
humans, although not in GnRH neurons. Furthermore,
the NDNF spatio-temporal expression pattern overlaps
the GnRH neuron migratory route. In addition to the
NDNF expression pattern, the positive effect of recom-
binant NDNF on GnRH neuron migration in vitro and
the migratory defect of GnRH neurons in both z-ndnf
MO-injected zebrafish and Ndnf-null mice provides
strong evidence for a role of NDNF in GnRH neuron
migration.
There are similarities between the two extracellular ma-
trix proteins NDNF and anosmin-1, which is encoded by
the first KS-related gene discovered, ANOS1. Indeed, both
contain FN3 domains that are critical for binding to hep-
aran sulfate proteoglycans.11,51 Anosmin-1 modulates
FGFR1 signaling via a direct interaction of the anosmin-
1-FN3 domain with heparan sulfate proteoglycan.56 Our
in vitro studies demonstrate that NDNF also modulates
FGFR1 signaling by inhibiting FGFR1-induced PLCg/Ca2þ
pathway activation after FGF8 stimulation. Thus, NDNF
could interact in vivowith FGF8, a well-knownmorphogen
acting during early developmental stages on the fate spec-
ification of GnRH neurons in the olfactory placode.
Further studies investigating this process in vivo are
needed.
Finally, NDNF promotes endothelial cell survival and
vessel formation and, thus, is a powerful angiogenic fac-
tor.57,58 NDNF modulates endothelial plasticity through
AKT/eNOS signaling,58 which is also known to be crucial
for GnRH release in the median eminence.59–61 This sug-
gests a possible role of NDNF in GnRH neuron biology
beyond embryonic development.
In conclusion, we have identified NDNF as a novel factor
involved in GnRH neuron ontogeny in humans and mice.
Identifying the molecular signaling pathway used by
NDNF in GnRH neuron ontogeny, along with the which
particular receptors and upstream and downstream targets
are involved, will be critical. Furthermore, it will also be
crucial to study the role of NDNF in the adult GnRH system
and homeostasis, specifically in regard to pubertal onset
and fertility.The AmSupplemental Data
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32. Spergel, D.J., Krüth, U., Hanley, D.F., Sprengel, R., and Seeburg,
P.H. (1999). GABA- and glutamate-activated channels in green
fluorescent protein-tagged gonadotropin-releasing hormone
neurons in transgenic mice. J. Neurosci. 19, 2037–2050.
33. Parkash, J., Cimino, I., Ferraris, N., Casoni, F., Wray, S., Cappy,
H., Prevot, V., and Giacobini, P. (2012). Suppression of b1-in-
tegrin in gonadotropin-releasing hormone cells disrupts020
migration and axonal extension resulting in severe reproduc-
tive alterations. J. Neurosci. 32, 16992–17002.
34. Giacobini, P., Parkash, J., Campagne, C., Messina, A., Casoni,
F., Vanacker, C., Langlet, F., Hobo, B., Cagnoni, G., Gallet, S.,
et al. (2014). Brain endothelial cells control fertility through
ovarian-steroid-dependent release of semaphorin 3A. PLoS
Biol. 12, e1001808.
35. Casoni, F., Malone, S.A., Belle, M., Luzzati, F., Collier, F., Allet,
C., Hrabovszky, E., Rasika, S., Prevot, V., Chédotal, A., and Gia-
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